Metabolic engineering of E. coli for improving mevalonate production to promote NADPH regeneration and enhance acetyl-CoA supply.
Daichi SatowaTsutomu TanakaShogo UchioMariko NakanoChisako OtomoYuuki HirataTakuya MatsumotoShuhei NodaTsutomu TanakaAkihiko KondoPublished in: Biotechnology and bioengineering (2020)
Microbial production of mevalonate from renewable feedstock is a promising and sustainable approach for the production of value-added chemicals. We describe the metabolic engineering of Escherichia coli to enhance mevalonate production from glucose and cellobiose. First, the mevalonate-producing pathway was introduced into E. coli and the expression of the gene atoB, which encodes the gene for acetoacetyl-CoA synthetase, was increased. Then, the deletion of the pgi gene, which encodes phosphoglucose isomerase, increased the NADPH/NADP+ ratio in the cells but did not improve mevalonate production. Alternatively, to reduce flux toward the tricarboxylic acid cycle, gltA, which encodes citrate synthetase, was disrupted. The resultant strain, MGΔgltA-MV, increased levels of intracellular acetyl-CoA up to sevenfold higher than the wild-type strain. This strain produced 8.0 g/L of mevalonate from 20 g/L of glucose. We also engineered the sugar supply by displaying β-glucosidase (BGL) on the cell surface. When cellobiose was used as carbon source, the strain lacking gnd displaying BGL efficiently consumed cellobiose and produced mevalonate at 5.7 g/L. The yield of mevalonate was 0.25 g/g glucose (1 g of cellobiose corresponds to 1.1 g of glucose). These results demonstrate the feasibility of producing mevalonate from cellobiose or cellooligosaccharides using an engineered E. coli strain.
Keyphrases
- escherichia coli
- blood glucose
- genome wide
- copy number
- stem cells
- cell surface
- wild type
- reactive oxygen species
- poor prognosis
- blood pressure
- skeletal muscle
- type diabetes
- cell proliferation
- oxidative stress
- molecular docking
- signaling pathway
- metabolic syndrome
- molecular dynamics simulations
- genome wide identification
- binding protein
- glycemic control